Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits
Author(s)
Chowdhury, Mohammed M; Singh, Kanwarpal; Albaghdadi, Mazen S; Khraishah, Haitham; Mauskapf, Adam; Kessinger, Chase W; Osborn, Eric A; Kellnberger, Stephan; Piao, Zhonglie; Lino Cardenas, Christian L; Grau, Madeleine S; Jaff, Michael R; Rosenfield, Kenneth; Libby, Peter; Edelman, Elazer R; Lindsay, Mark E; Tearney, Guillermo J; Jaffer, Farouc A; ... Show more Show less
DownloadPublished version (1.495Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
© 2020 The Authors Paclitaxel drug-coated balloons (DCBs) reduce restenosis, but their overall safety has recently raised concerns. This study hypothesized that DCBs could lessen inflammation and reduce plaque progression. Using 25 rabbits with cholesterol feeding- and balloon injury-induced lesions, DCB-percutaneous transluminal angioplasty (PTA), plain PTA, or sham-PTA (balloon insertion without inflation) was investigated using serial intravascular near-infrared fluorescence−optical coherence tomography and serial intravascular ultrasound. In these experiments, DCB-PTA reduced inflammation and plaque burden in nonobstructive lesions compared with PTA or sham-PTA. These findings indicated the potential for DCBs to serve safely as regional anti-atherosclerosis therapy.
Date issued
2020Department
Massachusetts Institute of Technology. Institute for Medical Engineering & ScienceJournal
JACC: Basic to Translational Science
Publisher
Elsevier BV